Little is known about breast cancer in Vietnamese women. Previous studies have reported the frequencies of prognostic factors of breast cancer in this population. The aim of this study was to examine the prognostic factors associated with the survival rates of patients with breast cancer treated at the National Cancer Hospital, Hanoi, Vietnam. We recruited 248 women with operable breast cancer treated with surgery and adjuvant therapy. Tumor tissue samples were stained by many immunohistochemical approaches and analyzed for estrogen receptor, progesterone receptor, and HER2 gene amplification status. A Cox model was used to determine the relationship between survival and the prognostic factors. The disease-free survival rate, overall survival rate, and cancer-specific survival rate were 75.8%, 80.6%, and 86.4%, respectively, at 5 years and 62.3%, 68.1%, and 78.9%, respectively, at 10 years. The lung was the most common metastatic site. Women with factors associated with a poor prognosis (eg, advanced clinical stage, high tumor grade, progesterone receptor [PR] negativity, HER2 amplification) had significantly lower survival rates. Patients with PR-negative breast cancer had significantly worse survival rates compared to those who were PR positive, according to multivariate analysis (hazard ratio = 1.77, 95% confidence interval: 1.01-3.11, P = .045); however, there was only a statistically significant difference in postmenopausal patients. The PR was a prognostic factor in postmenopausal women with breast cancer, but not in premenopausal women.

Background Mutations of the KRAS gene are common in cancers; they are detected at a very high rate in colon cancer (CC) and are considered a negative disease factor. CC is among the deadliest cancers in Vietnam, and KRAS status for non-polyp colon cancer (NPCC) was rarely reported from the country. In this study, we aim to determine KRAS mutations and the associations of mutation status with clinicopathological features in Vietnamese NPCC patients. Methods Patients with NPCC (stages II or III) and without historical or current polyp appearance were included. Genomic DNA samples were prepared from dissected tumors, and specific sequences of the KRAS gene were amplified by PCR. The mutations at codons 12, 13, 59, 60, 61, 117, and 146 of the gene were determined by using a commercial kit. Possible associations of the KRAS mutation with clinicopathological properties were analyzed using SPSS and GraphPad Prism. Results The KRAS mutation rate was 47.9% in NPCC patients; mutations in exon 2 accounted for 91.4% of all detected mutations. Moreover, the KRAS mutation rate was higher in females (57.1%) than in males (39.8%). The association of KRAS mutation with female NPCC patients was further confirmed by multivariate regression data with OR=2.144 and p = 0.012. Conclusion The KRAS mutation rate was also higher in patients with right colon cancers. The mutated-KRAS-carrying patients potentially experienced anemia. The data provide important scientific background for the treatment and management of the disease.

Background: Mutations of KRAS gene are common in cancers; they are detected at a very high rate in colon cancer (CC) and considered the negative factor of the disease. CC is among deadliest cancers in Vietnam, and KRAS status for non-polyp colon cancer (NPCC) was rarely reported from the country. We, in this study, aim to determine KRAS mutations and associations of mutation status with clinicopathological features in Vietnamese NPCC patients. Methods: Patients with NPCC (stages II or III) and without historical or current polyp appearance were included. Genomic DNA samples were prepared from dissected tumors and specific sequences of KRAS gene were amplified by PCR. The mutations at codons 12, 13, 59, 60, 61, 117 and 146 of the gene were determined by using a commercial kit. Possible associations of the KRAS mutation with clinicopathological properties were analyzed by using SPSS and GraphPad Prism. Key findings: KRAS mutation rate was 47.9% in NPCC patients; mutations in exon 2 accounted for 91.4% of all detected mutations. Moreover, the KRAS mutation rate was higher in females (57.1%) than in males (39.8%).